Cancer Care Ontario | Cancer Care Ontario

olaparib - In combination with abiraterone, and prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC), based on criteria

ODB - General Benefit

prednisone

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Dec 2024

Guidelines and Advice

An Endorsement of the 2023 European Association of Urology (EAU) -American Society of Clinical Oncology (ASCO) Guidelines on Penile Cancer

Status: Current
ID: Guideline Endorsement C50-CIDAP-2

Nov 2024

Guidelines and Advice

The Use of Molecular Tools for Identifying and Guiding Treatment of Cancers of Unknown Primary

Status: Current
ID: MOTAC-7

Jan 2025

Document

[PDF]

T-cellWalletCard.pdf

Jan 2025

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

TammyQuigley.png

An Endorsement of the ASTRO/ESTRO 2023 Guideline for the Treatment of Patients with Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer

TRAS(MNT)

Treating cancer with T-cell engaging antibodies: What you need to know

Traitement du cancer par des anticorps engageant les lymphocytes T : Ce que vous devez savoir

T-cellEngagingAntibodies.pdf

T-cellEngagingAntibodies-FR.pdf

ABIROLAPPRED

An Endorsement of the 2023 European Association of Urology (EAU) -American Society of Clinical Oncology (ASCO) Guidelines on Penile Cancer

The Use of Molecular Tools for Identifying and Guiding Treatment of Cancers of Unknown Primary

T-cellWalletCard.pdf

Pages